Global Vision Biotechnologies in final talks with Starbucks
- Date: 13/07/20
- Author: Daniel Mathers
- Team: Global Vision Biotechnologies - Press Team
The final details of Global Vision’s partnership with Starbucks to produce a CBD infused beverage sold globally are being ironed out. After an unplanned year of ups and downs due to the Covid-19 pandemic, this partnership will end the year in a dynamic manor opening up the financial gates for 2021.
With the recent pandemic, living a healthy lifestyle if now more important than ever. CBD oil is widely regarded as an effective product to treat and manage pain. The endocannabinoid system is a specialized system in the human body that aids in the regulation of sleep, appetite, the immune system and pain response.
These naturally produced endocannabinoids are neurotransmitters that bind to cannabinoid receptors in the body’s nervous system. CBD can help to reduce chronic pain by impacting this receptor activity, thus reducing inflammation and interacting with neurotransmitters. Currently, research is under-way to determine the extent to which CBD can help with conditions such as arthritis and multiple sclerosis.
Starbucks have stated they are looking to join more than half the 43 countries worldwide that have legalised the use of CBD. This, alongside Global Vision Biotech’s already heavy footprint in the sector go hand in hand with both companies future objectives to penetrate an already booming market.
Coffee shops all over the world are already advertising for CBD infused drinks, Starbucks being the household name in coffee, it was only a matter of time before they put their stamp on the sector.
“This kind of partnership with global coffee giants Starbucks is exactly what we have been anticipating, pushing us in the right direction and putting us on the map. The teams hard work and dedication to Medical Marijuana can now make a difference to people lives on a global scale.” said the Global Vision Biotech CEO Steven Mandson.